197 related articles for article (PubMed ID: 31097390)
1. A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.
Kao C; McNamara M; Alley C; Spector N; Jauhari S; Gupta RT; Zhang T; Zhu J
Clin Genitourin Cancer; 2019 Jun; 17(3):e672-e677. PubMed ID: 31097390
[No Abstract] [Full Text] [Related]
2. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT;
BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for the treatment of bladder cancer.
Sundahl N; Rottey S; De Maeseneer D; Ost P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
Sheth S; Weiss J
Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.
Hahn AW; Chahoud J; Campbell MT; Karp DD; Wang J; Stephen B; Tu SM; Pettaway CA; Naing A
Invest New Drugs; 2021 Oct; 39(5):1405-1410. PubMed ID: 33770291
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer: A Case Report and Literature Review.
Muramatsu-Maekawa Y; Taniguchi T; Ito H; Nakane K; Kato T; Tsuchiya T; Miyazaki T; Koie T; Mizutani K
J Immunother; 2020 May; 43(4):134-138. PubMed ID: 32080020
[TBL] [Abstract][Full Text] [Related]
8. Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma.
Miyama Y; Morikawa T; Miyakawa J; Koyama Y; Kawai T; Kume H; Ushiku T
Pathol Res Pract; 2021 Mar; 219():153364. PubMed ID: 33610951
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant pembrolizumab in bladder cancer.
Gourd E
Lancet Oncol; 2018 Dec; 19(12):e669. PubMed ID: 30509883
[No Abstract] [Full Text] [Related]
10. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
[TBL] [Abstract][Full Text] [Related]
11. Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature.
Wilde L; Ali SM; Solomides CC; Ross JS; Trabulsi E; Hoffman-Censits J
Clin Genitourin Cancer; 2017 Jun; 15(3):e521-e524. PubMed ID: 28143711
[No Abstract] [Full Text] [Related]
12. Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report.
Song HN; Kang MG; Park JR; Hwang JY; Kang JH; Lee WS; Lee GW
Cancer Res Treat; 2018 Oct; 50(4):1458-1461. PubMed ID: 29361819
[TBL] [Abstract][Full Text] [Related]
13. A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer.
Rassy EE; Bakouny Z; Aoun F; Haddad FG; Sleilaty G; Assi T; Kattan J
Immunotherapy; 2018 Jun; 10(8):657-663. PubMed ID: 29562804
[TBL] [Abstract][Full Text] [Related]
14. Three more immune checkpoint inhibitors for advanced bladder cancer.
Med Lett Drugs Ther; 2017 Dec; 59(1535):e202-e203. PubMed ID: 29186087
[No Abstract] [Full Text] [Related]
15. Advanced Bladder Cancer Rechallenged With an Immune Checkpoint Inhibitor: A Case Report.
Bat T; Buck DA; Nathan R; Cinquino J; Sikorski M; Elefante A; Herbst L; Sule N; Fabiano A; George S
Urology; 2019 Sep; 131():24-26. PubMed ID: 31059726
[No Abstract] [Full Text] [Related]
16. Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis?
Capurso G; Archibugi L; Tessieri L; Petrone MC; Laghi A; Arcidiacono PG
Eur J Cancer; 2018 May; 95():123-126. PubMed ID: 29530539
[No Abstract] [Full Text] [Related]
17. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
18. NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
Gupta S; Kamat AM
Nat Rev Urol; 2020 Sep; 17(9):491-492. PubMed ID: 32632305
[TBL] [Abstract][Full Text] [Related]
19. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
[No Abstract] [Full Text] [Related]
20. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.
Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E
Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
